Fermenta Biotech Limited
CIN: L99999MH1951PLC008485
Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road,
Majiwade, Thane (W) - 400 610, Maharashtra, India.
Tel. : +91-22-6798 0888 Email : info@fermentabiotech.com,
Website : www.fermentabiotech.com

August 11, 2026

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: **506414**

National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1,
G Block, Bandra - Kurla Complex,
Bandra (East), Mumbai 400 051
Trading Symbol: **FERMENTA**

Dear Sir,

Sub.: Intimation of Earnings Presentation – Q1/FY27

Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Earnings Presentation for Q1/FY27 for your information.

The said Earnings Presentation will thereafter be uploaded on Company's website at www.fermentabiotech.com

This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Kindly take the same on records.

Thanking you,

Yours faithfully,
for **FERMENTA BIOTECH LIMITED**

VARADVINAYAK VIJAY KHAMBETE
Digitally signed by VARADVINAYAK VIJAY KHAMBETE
Date: 2026.08.11 13:42:19 +05'30'

Varadvinayak Khambete
Company Secretary and Head - Legal
Membership No. A33861

Encl: As above

fermenta

Fermenta Biotech Ltd

Q1FY27 presentation

11 August 2026

Disclaimer

By viewing this presentation, the recipient agrees that neither Fermenta Biotech Limited ("FBL") nor any of its affiliates, directors, officers, employees, or representatives shall be liable for any loss, damage, or liability arising directly or indirectly from the use of or reliance on the information contained herein. The recipient further agrees to indemnify and hold harmless FBL and its representatives from any claims, losses, or damages arising out of or related to any unauthorized use or distribution of this material or any breach of these terms.

This presentation may contain forward-looking statements relating to FBL)s future business, financial performance, industry trends, strategy, or objectives. These statements are based on current assumptions and expectations and involve known and unknown risks and uncertainties that may cause actual results to differ materially. Factors such as economic conditions, regulatory changes, market dynamics, technological developments, and global events could impact future outcomes.

Forward-looking statements are identified by terms such as "expects" "intends" "may" "believes" "plans" "will" and similar expressions. FBL undertakes no obligation to revise or update these statements. This presentation does not constitute an offer or invitation to buy or sell securities and should not be relied upon for any investment decisions.

As preventive healthcare awareness rises, global demand is accelerating for science-backed, top-quality nutritional ingredients.
Fermenta pairs process and molecular expertise with science-validated capability to deliver best-in-class ingredients, trusted by leading brands across the pharmaceutical, dietary supplement, food and beverage, veterinary, and animal nutrition industries.

Our edge: decades of global-scale, complex manufacturing and research-driven custom solutions in green chemistry, APIs and intermediates, and environmental solutions. Chemistry built to solve, engineered to scale, and proven in the field by 400+ discerning customers across 60+ countries.

Q1FY27 Highlights

Financials (consolidated) with and without Real Estate

	Q1FY27	Q1FY27 ex-real estate
Revenue	INR 126.2 crore (down 13% YoY, flat QoQ)	INR 124.3 crore (down 12% YoY, flat QoQ)
EBITDA	INR 22.4 crore (down 39% YoY, down 11% QoQ)	INR 22.3 crore (down 37% YoY, down 10% QoQ)
Profit after tax	INR 9.5 crore (down 56% YoY, down 49% QoQ)	—
EPS (diluted)	INR 3.34	—

The YoY comparison is against an exceptionally strong April–June 2025 base, which carried INR 2.7 crore of non-recurring insurance income and INR 1.6 crore of real-estate value unlocking; neither recurs in the current quarter. Sequential human nutrition growth and stronger India reaffirm Fermenta's structural direction.

Performance

Revenue near flat sequentially at INR 126.2 crore, flat QoQ, with human nutrition revenue up 24% QoQ to INR 76.5 crore and segment volumes up 18% QoQ across Fermenta's largest business.

India strengthened as a market, rising to 47% of consolidated revenue in April–June 2026 from 35% a year earlier, as domestic demand deepened across nutrition and APIs.

Growth broadens beyond Vitamin D3: Other APIs and Intermediates up 18% YoY to INR 11.6 crore, Green Chemistry Solutions / Enzymes up 15% YoY to INR 2.3 crore, and Others within nutrition up 28% YoY to INR 11 crore.

Animal nutrition remains the soft spot: volumes down 52% QoQ and 20% YoY with average realisation down 40% YoY; the Company chose volume discipline over chasing a weak price.

Two post-quarter milestones: FSSAI approval for VITADEE Green® (6 July 2026) for health supplements, nutraceuticals and food products; and a 7th-place ranking nationwide in India's Great Mid-size Workplaces™ 2026.

Lines of Business

Nutrition

Primary revenue source focused on nutritional ingredients for health and wellness industries

Vitamin D3 – Human

Premium supplements, food fortification, and pharmaceuticals for nutraceutical companies, food processors, and pharmaceutical firms

Vitamin D3 – Animal

Specialized formulations for livestock and poultry feed applications targeting animal feed manufacturers, poultry farms, and dairy producers

Others

Customized Food Premixes, Fortified Rice Kernels (FRK) and Specialized Nutraceutical Ingredients

Others

Diversified biotechnology and chemical solutions for industrial and environmental applications

API & Intermediates

Pharmaceutical ingredients and custom synthesis for generic drug manufacturers and pharmaceutical developers

Green Chemistry

Enzymatic technologies for eco-friendly processes serving chemical manufacturers, biofuel producers, and cosmetic companies

Environmental

Biotechnolgy-based remediation solutions for for water treatment and waste management sectors

Revenue Mix (Consolidated)

	Q1FY27 (INR crore)	Q4FY26 (INR crore)	QoQ change (%)	Q1FY26 (INR crore)	YoY change (%)
Nutrition Business					
Vitamin D3 – Human Nutrition	76.5	61.7	+24%	84.7	-10%
Vitamin D3 – Animal Nutrition	12.6	22.9	-45%	21.4	-41%
Others	11.0	9.5	+16%	8.5	+28%
Other Business					
Other APIs and Intermediates	11.6	18.1	-36%	9.8	+18%
Green Chemistry Solutions / Enzymes	2.3	6.9	-67%	2.0	+15%
Environmental Solutions	6.0	0.8	+619%	6.6	-8%
Other Income	6.2	6.7	-8%	10.4	-41%
Value Unlocking					
Real Estate	0	0	-100%	1.6	-100%

Geographical Revenue Mix (consolidated) excluding real estate value unlocking



Income Statement—Key Numbers (Consolidated)

Amount in INR crore	Q1FY27	Q1FY26	% Change
INCOME			
Revenue from operations	121.8	136.3	
Other income	4.4	8.8	
Total Income	**126.2**	**145.0**	**-13%**
EXPENSES			
Cost of materials consumed*	38.8	27.5	
Purchases of stock-in-trade	9.8	15.6	
Change in inventories	(6.5)	8.8	
Employee benefits expense	23.0	20.4	
Finance costs	2.5	3.1	
Depreciation and amortisation	5.2	5.8	
Other expenses	38.7	35.7	
Total Expenses	**111.5**	**116.9**	
PROFITABILITY			
Profit before tax	14.7	28.1	
Tax expense	5.2	6.6	
Profit after tax	**9.5**	**21.6**	**-56%**

The YoY comparison is against a strong April–June 2025 base: human nutrition volumes rose 18% QoQ, India reached 47% of revenue, and there are no exceptional items in the quarter

** Net of the INR 2.0 crore non-cash write-back of the earlier inventory write-down*

Cost Breakdown (Without Real Estate)

Cost Structure Against the FY26 Base

(% of Revenue)

Cost Component	Q1FY27	FY26	FY25
Raw Materials	35%	37%	38%
Employee Costs	19%	16%	15%
Manufacturing Expenses	12%	12%	15%
Sales & Marketing	5%	5%	4%
Administrative	13%	11%	10%
Finance Costs	2%	2%	3%

Raw materials at 35% of revenue in Q1FY27, against 37% in FY26 and 38% in FY25

Employee costs at 19%, against 16% in FY26

Manufacturing expenses at 12%, against 12% in FY26

Finance costs at 2%, against 2% in FY26

Raw material costs at 35% of revenue in Q1FY27, against 37% in FY26 (38% in FY25), which reflected an improved sourcing mix.

Employee costs at 19% of revenue, against 16% in FY26, when capacity expansion added heads ahead of the Dahej scale-up.

Manufacturing expenses at 12% in Q1FY27, against 12% in FY26, which had improved from 15% in FY25 on operating leverage from higher volumes.

Sales & marketing spend at 5%, against 5% in FY26, which reflected a wider market development push.

Finance costs at 2%, against 2% in FY26 and 3% in FY25, on continued deleveraging.

The Opportunity

Unlocking growth: Fermenta's unique position to meet evolving health and nutrition demands worldwide

India

- ✓ Preventive health awareness
- ✓ Growing middle class
- ✓ Govt initiatives / PLI
- ✓ Food fortification
- ✓ Functional food growth
- ✓ Animal nutrition demand
- ✓ Pharma & API localisation

Global

- ✓ Nutritional supplements
- ✓ Ageing drives vitamin D
- ✓ Fortified food markets
- ✓ Clean-label growth
- ✓ Pet nutrition market
- ✓ Prevention over cure
- ✓ Green chemistry demand

Innovation Drivers

- ✓ Plant-source actives
- ✓ Biocatalysis & green chemistry
- ✓ Advanced delivery

Industry-wide Trends

- ✓ Green innovation
- ✓ New delivery systems
- ✓ Biocatalysis & enzymes
- ✓ Supply-chain visibility
- ✓ Immune health focus

Regulatory Opportunities

- ✓ Evolving regulations
- ✓ Global standards
- ✓ Science-validated efficacy

Strategy Map

Our Mission To harness our expertise in Innovation Chemistry and complex manufacturing at scale, delivering science-validated, leading-class solutions across nutrition, health and green chemistry, while creating lasting value for customers, society and investors

Financial

Financial Performance and Investor Value

- Deliver consistent, industry-leading returns and cash generation
- Optimise asset value and unlock capital from non-core assets
- Sustain growth through disciplined organic investment and selective acquisitions
- Maintain a strong, deleveraged balance sheet

Sales

Customer-Centric Approach

- Target key sectors: pharma, nutrition, food and beverages, veterinary, and custom premixes
- Exceed the science-validated quality standards demanded by global industry leaders
- Deepen strategic relationships with premier brands across health and nutrition

Expansion

Market Expansion & Inorganic Growth

- Extend global leadership in Vitamin D3, including differentiated plant-source D3
- Deepen the 60-plus country footprint and open new geographies, including the EU via EDQM CEP
- Pursue selective acquisitions and partnerships that expand capabilities and markets
- Integrate complementary technologies to accelerate the Innovation Chemistry pipeline

Internal Process

Operational Excellence

- Scale advanced, integrated manufacturing across Dahej, Kullu and Tirupati
- Draw on decades of complex, high-value chemistry expertise
- Drive efficiency and margins through process innovation and green chemistry

Innovation and Product Development

- Deploy Innovation Chemistry and R&D to create science-validated products
- Broaden the portfolio across vitamins, biocatalysis and enzymes, premixes and intermediates
- Deliver targeted, research-led solutions to specific customer challenges

Sustainability and Social Responsibility

- Advance global health through science-validated preventive nutrition and actives
- Enhance wellbeing and productivity across human and animal populations
- Lead on sustainability through green chemistry and lower-footprint processes

Organizational Learning

Capability Development

- Build research and process capabilities at the frontier of Innovation Chemistry
- Cultivate cross-functional expertise across sectors, geographies and technologies

accelerate growth | diversify the portfolio | strengthen global leadership

Manufacturing and R&D

100+
Scientists & Engineers

15+
Key Certifications

75+
Years of Expertise

400+
Global Customers

Strategic Manufacturing Footprint

Breakthrough Capabilities at Global Scale

Global Trust Indicators

Strategic Partnership Ecosystem

fbl fermenta

		The Collaboration	Strategic Value
Abbott	Global healthcare company specializing in diagnostics, medical devices, and nutrition	Vitamin D awareness campaigns Print and audiovisual educational materials	Extends our reach to healthcare professionals and patients
NIFTEM KUNDLI ज्ञान · नवोन्मेष · विस्तार	Premier food technology institute under Ministry of Food Processing Industries	Fortification of biscuits and juices with VITADEE Green® Development of Fortified Rice Kernels (FRK)	Adds government-backed credibility to our fortification initiatives
informa markets	Leading global exhibition organizer for multiple industries	Exhibition participation · Conference sponsorship Vitamin D awareness activities	Enhances market visibility and creates industry networking opportunities
HADSA Health Foods And Dietary Supplements Association	Health Food and Dietary Supplements Association for nutraceuticals in India	Committee membership for annual conference Platinum sponsorship CEO panel discussions and speaker sessions	Strengthens our position in India's regulatory and industry landscape
gain Global Alliance for Improved Nutrition	Global Alliance for Improved Nutrition combating worldwide malnutrition	Supporting DFQT+ digital traceability solution Improving quality assurance in fortification programs	Demonstrates our commitment to global nutrition challenges

Amplifies market reach | enhances technical capabilities | strengthens industry influence | expands social impact

Across the entire nutrition and fortification value chain

FBL Certifications

Comprehensive certifications demonstrate our commitment to meet diverse customer needs and global standards of quality, safety, sustainability, and ethical production.

EDQM	Adherence to stringent guidelines for European pharmaceutical markets
KLBD	Confirms ingredients and manufacturing processes comply with community-specific dietary requirements
BRC Certification Body	Compliant with Global food safety standards
Jamiat Ulama Halal Foundation (HALAL 0965)	Confirms ingredients and manufacturing processes comply with community-specific dietary requirements
Certified American Vegetarian Association; Vegetarian Society Approved	Vegetarian friendly
Vegan	Meeting global vegan standards
WFP World Food Programme	Approval for participating in United Nations Rice Fortification Programs
NSF	GMP approval for dietary supplements
FSSC 22000	Ensures global food safety management
Intertek	Tests, inspects, and certifies products to meet quality and safety standards across industries
FDA U.S. Food & Drug Administration	US regulatory approval for safety standards involving food and dietary supplements
WHO GMP Certified	Ensures products are consistently produced according to quality standards appropriate for their intended use and as required by marketing authorization
FAMI-QS	For specialty feed ingredients and their mixtures, ensuring feed safety in the animal nutrition industry
Certified HACCP Food Safety	Systematic preventive approach to food safety that identifies, evaluates, and controls hazards in the production process
gain Global Alliance for Improved Nutrition	GAIN Premix Facility approval for global micronutrient premix tenders

Note: *Product specific; site specific*

R&D Focus Areas & Achievements

fbl fermenta

	Focus	Key Achievements	Future Directions
API	Product pipelines Process improvement Yield enhancement	Commercialized 11 products including Cholesterol, Lanolin derivatives Enhanced Phenyramidol HCl process	Calcifediol commercialization VITADEE Green® VITADEE™ SD (Spray Dried) Lanolin derivatives for cosmetics, lubricants
Biotechnology	Molecular biology Fermentation	Tripled enzyme activity (PA 850, PS 250) Developed in-house TL Lipase & Dual Locus Created 'Penmox Enzyme' for one-pot synthesis Patented technologies	New lipase portfolio API enzyme applications Oleochemistry & Biodiesel
Pre-formulation	New ingredient versions Premix development Pilot-scale Innovation	Commercialized 10 vitamin products Developed premixes for multiple categories (rice, flour, oil, milk fortification)	Calcifediol 1.25% commercialization WFP FRK premix development RUSF & RUTF premixes

Strategic Portfolio for Future Growth

Spray-Dried Vitamin D3

- ✓ 100,000 IU/g pharmaceutical-grade technology with CEP certification
- ✓ From the pioneers of Vitamin D3
- ✓ Premium Application: Superior stability for pharmaceutical formulations
- ✓ Strategic Advantage: Essential European market access certification

VITADEE Green®

- ✓ Plant-based Vitamin D3 with clean-label for vegan supplement markets
- ✓ Market Differentiator: Phytosterol-derived vegan alternative
- ✓ Quality Assurance: Only Multi-compendial standards of Vitamin D3 40 MIU/g purity
- ✓ Competitive Edge: Higher purity & stability vs lichen-derived options
- ✓ Market Expertise: 75+ years manufacturing experience

Calcifediol

- ✓ Next-generation Vitamin D metabolite for nutrition and therapeutics
- ✓ Therapeutic Relevance: Clinical correction of Vitamin D deficiency
- ✓ Funded Scale-Up: Capacity committed in the ₹110 crore Dahej capex
- ✓ Launch Readiness: Approaching final validation as clinical demand opens
- ✓ Portfolio Breadth: 1.25% grade for advanced animal nutrition

Customized Premixes

- ✓ Equipped with advanced instrumentation and pilot-scale equipment, the lab allows us to simulate real-world manufacturing conditions, conduct small-scale formulation trials, and rapidly iterate based on customer feedback
- ✓ Collaborates closely with clients to co-develop solutions that are tailored to specific application needs—whether it's for dietary supplements, functional foods, or beverages
- ✓ Ensures that every premix is designed for optimal uniformity and shelf-life stability, delivering reliable performance in both dry and liquid formats

Clean-Label Growth Opportunity | Pharmaceutical Leadership Position
Limited Competition Advantage

Fermenta's Core Proposition

Society

Advance global health and preventive care through science-validated ingredients and actives

Support life and productivity across human and animal populations

Address environmental challenges through green chemistry and sustainable processes

Customers

Best-in-class, science-validated ingredients, actives and intermediates

Diverse market segments: pharmaceuticals, nutrition, food and beverages, veterinary, and customised vitamin mineral premixes

Meet the exacting standards of leading global brands across pharma, nutrition, food and animal health

Research-based custom solutions tailored to specific needs

A comprehensive portfolio spanning vitamins, biocatalysis and enzymes, custom premixes and green chemistry

Our core vision

Better living for all

Through Innovation Chemistry

For a healthier, more sustainable world

Investors

Leadership in Vitamin D3, including differentiated plant-source D3, protected by process patents and regulatory approvals (EDQM CEP, US FDA, EU GMP)

Innovation Chemistry moat: proprietary biocatalysis and green chemistry

Integrated, backward-integrated model securing key inputs

Lower environmental footprint while improving bioavailability

Strong and improving returns and cash generation

Deleveraged, liquid balance sheet funding a visible growth pipeline (plant-source D3, calcifediol, biocatalysis enzymes)

Disciplined capital allocation

Diversified, high-value revenue across products, segments and geographies, reducing concentration risk, with optionality from non-core assets

Deep, sticky relationships with leading global brands, underpinning durable, compounding growth

Thank you

Sumesh Gandhi – CFO

sumesh.gandhi@fermentabiotech.com

Fermenta Biotech Ltd